Page 6 - HFA_Dateline_2017_Q2_Fall_Special_Edition
P. 6

30

Product Evolution: Decades of Innovation

20 Total on Market

                                                                                                  14
F 1 Number of Products Released to Market
     or most of the 20th century, people living with hemophilia common cause of death among adolescents who suffered from
     struggled with health problems. Up until the late 1960s,       hemophilia. 8
                                                                                                                                             5
tre1a0tment was limited to whole-blood transfusions and icing       It’s hard for those who didn’t live through the ‘60s to imagine
                                                                    the impact that the first clotting factor product had on the
joints, a procedure that required days in the hospital to recov-    community when it was administered to a hemophilia patient
                                                                    for the first time in 1967. By early 1968, factor concentrate had
er from a bleed. After cryoprecipitate, a faster, more effective
                                                                    en2tered3trials4for h5ome6treatm7ent and the comm1 uni2ty beg3an 4
treatment for bleeding episode1s, was developed in 1964 by Dr.
Judith Graham Pool, life expectancy rose to just o1ver 39 years, 1  to experience a paradigm shift, suddenly filled with hope that

   0 a vast improvement from the                                    children l1i9vi7ng0wsith hemophilia would be able to live fu1l9ler8, 0s
                            19602s7-year median life expec-
                                                                    healthier, and considerably longer lives.
                                          tancy during the decades
                                                                    The Hemophilia Act of 1973 allowed the establishment of fed-
                                           that preceded.           erally-funded comprehensive Hemophilia Treatment Centers
                                                                    (HTCs). Today, there are more than 140 HTCs and programs
The success with treatment                                          across the country. This, along with a growing national focus
brought new challenges that                                         on people living with hemophilia, led to a sharp increase in
few in the community could                                          positive outcomes for hemophilia patients, as life expectancy
have envisioned. As life ex-                                        rose to 60 years old.
pectancy grew, it brought
with it new side effects,
questions, and concerns for

psychiatrists, social work-

ers, and community mem- “T oday, there are more than 140 HTCs

bers as they dealt with the social complications that go along and programs across the country.”

with having a crippling illness. Suicide was, in fact, the most

Bleeding Disorder Products
Released to Market

       Total Number of Products on the Market                                         14
X Number of Products Released to Market
                                                                              12
   1                                              1                    8      3456
1960s
                                                                        1 23       1980s
                                                                       4567
                                                                    1970s

6	 Dateline Federation | Special Issue Fall 2017
   1   2   3   4   5   6   7   8   9   10   11